Use of replicating oncolytic adenoviruses in combination therapy for cancer.
Oncolytic virotherapy is the use of genetically engineered viruses that specifically target and destroy tumor cells via their cytolytic replication cycle. Viral-mediated tumor destruction is propagated through infection of nearby tumor cells by the newly released progeny. Each cycle should amplify the number of oncolytic viruses available for infection. Our understanding of the life cycles of cytolytic viruses has allowed manipulation of their genome to selectively kill tumor cells over normal tissue. Because the mechanism of tumor destruction is different, oncolytic virotherapy should work synergistically with current modes of treatment such as chemotherapy and radiation therapy. This article focuses on oncolytic adenoviruses that have been created and tested in preclinical and clinical trials in combination with chemotherapy, radiation therapy, and gene therapy.
Laboratory of Molecular Neuro-Oncology, Departments of Neurosurgery, Hematology/Oncology, and Winship Cancer Institute, Emory University, Atlanta, Georgia, USA.
Roland L
RL
Chu
Dawn E
DE
Post
Fadlo R
FR
Khuri
Erwin G
EG
Van Meir
D000256:Adenoviridae / Q000502:physiology*; D000818:Animals; D002986:Clinical Trials as Topic; D003131:Combined Modality Therapy; D006801:Humans; D009369:Neoplasms / Q000473:pathology* / Q000628:therapy*; D014779:Virus Replication / Q000502:physiology*